Hepatitis Forums

Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on July 15, 2019, 10:54:35 am

Title: Viread Hep B Treatment May Reduce Liver Cancer Risk More Than Baraclude
Post by: Hep Editors on July 15, 2019, 10:54:35 am
People with hepatitis B who were treated with Viread (tenofovir disiproxil fumarate) were found to be less likely to develop hepatocellular carcinoma (HCC) than those treated with Baraclude (entecavir), according to results from a large observational study presented at the 2019 International Liver Congress last week in Vienna.

The analysis included nearly 30,000 people, but only a small proportion of them had used Viread. Although the researchers attempted to control for other factors that might affect outcomes, it may be too early to declare that Viread is a superior option.